Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
Alimena
G
G
Breccia
M
M
Mancini
M
M
Ferranti
G
G
De Felice
L
L
Gallucci
C
C
Mandelli
F
F
D001549:Benzamides; D002898:Chromosomes, Human, Pair 8; D002999:Clone Cells / Q000473:pathology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000139:chemically induced* / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000209:etiology / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014314:Trisomy
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate